{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:26:43Z","timestamp":1696948003328},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,5,11]],"date-time":"2013-05-11T00:00:00Z","timestamp":1368230400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s10067-013-2240-4","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T05:28:41Z","timestamp":1368163721000},"page":"1275-1281","source":"Crossref","is-referenced-by-count":15,"title":["Induction of response with etanercept\u2013methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study"],"prefix":"10.1007","volume":"32","author":[{"given":"Karel","family":"Pavelka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nemanja","family":"Damjanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Majdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeny","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim","family":"Mazurov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Fabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eustratios","family":"Bananis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Szumski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boxiong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Kotak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu","family":"Vasilescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,11]]},"reference":[{"key":"2240_CR1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2011","unstructured":"Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2011) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964\u2013975","journal-title":"Ann Rheum Dis"},{"key":"2240_CR2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D, T2T Expert Committee (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631\u2013637","journal-title":"Ann Rheum Dis"},{"key":"2240_CR3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, Van\u2019tHof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel RL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348","journal-title":"Arthritis Rheum"},{"key":"2240_CR4","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796\u2013R806","journal-title":"Arthritis Res Ther"},{"key":"2240_CR5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42:244\u2013257","journal-title":"Rheumatology (Oxford)"},{"key":"2240_CR6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404\u2013413","journal-title":"Ann Rheum Dis"},{"key":"2240_CR7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3899\/jrheum.080663","volume":"36","author":"E Keystone","year":"2009","unstructured":"Keystone E, Freundlich B, Schiff M, Li J, Hooper M (2009) Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. J Rheumatol 36:522\u2013531","journal-title":"J Rheumatol"},{"key":"2240_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-122-2-199501150-00001","volume":"122","author":"BC Tilley","year":"1995","unstructured":"Tilley BC, Alarc\u00f3n GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JC, Buckley L, Cooper SM, Duncan H, Pillemer SR, Tuttleman M, Fowler SE (1995) Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. MIRA trial group. Ann Intern Med 122:81\u201389","journal-title":"Ann Intern Med"},{"key":"2240_CR9","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s10198-007-0088-8","volume":"8","author":"J Lundkvist","year":"2008","unstructured":"Lundkvist J, Kast\u00e4ng F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8:S49\u2013S60","journal-title":"Eur J Health Econ"},{"key":"2240_CR10","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1007\/s10198-007-0090-1","volume":"8","author":"J Lundqvist","year":"2008","unstructured":"Lundqvist J, Kast\u00e4ng F, Kobelt G, Jonsson B (2008) The burden of rheumatoid arthritis and access to treatment: determinants of access. Eur J Health Econ 8:S87\u2013S93","journal-title":"Eur J Health Econ"},{"key":"2240_CR11","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10198-007-0085-y","volume":"8","author":"B Jonsson","year":"2008","unstructured":"Jonsson B, Kobelt G, Smolen J (2008) Patient access to rheumatoid arthritis treatments. Eur J Health Econ 8:S33\u2013S34","journal-title":"Eur J Health Econ"},{"key":"2240_CR12","doi-asserted-by":"crossref","first-page":"SR1","DOI":"10.12659\/MSM.881697","volume":"17","author":"E Orlewska","year":"2011","unstructured":"Orlewska E, Ancuta I, Anic B, Codrenau C, Damjanov N, Djukic P, Ionescu R, Marinchev L, Nasonov EL, Peets T, Praprotnik S, Rashkov R, Skoupa J, Tlustochowicz W, Tlustochowicz M, Tomsic M, Veldi T, Vojinovic J, Wiland P (2011) Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit 17:SR1\u2013SR13","journal-title":"Med Sci Monit"},{"key":"2240_CR13","first-page":"12","volume":"52","author":"Hungarian College of Rheumatology and Physiotherapy","year":"2011","unstructured":"Hungarian College of Rheumatology and Physiotherapy (2011) The treatment of arthritis with synthetic and biological disease modifying drugs. Hung Rheumatol 52:12\u201327","journal-title":"Hung Rheumatol"},{"key":"2240_CR14","first-page":"182","volume":"4","author":"K Pavelka","year":"2010","unstructured":"Pavelka K, Vencovsky J (2010) Recommendations of Czech Rheumatological Society for treatment of rheumatoid arthritis [in Czech]. Ces Revmatol 4:182\u2013191","journal-title":"Ces Revmatol"},{"key":"2240_CR15","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","volume":"381","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381:918\u2013929","journal-title":"Lancet"},{"key":"2240_CR16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727\u2013735","journal-title":"Arthritis Rheum"},{"key":"2240_CR17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/annrheumdis-2011-201066","volume":"71","author":"P Emery","year":"2012","unstructured":"Emery P, Kvien TK, Combe B, Freundlich B, Robertson D, Ferdousi T, Bananis E, Pedersen R, Koenig AS (2012) Combination etanercept and methotrexate provides better disease control in very early (\u22644\u00a0months) versus early rheumatoid arthritis (>4\u00a0months and <2\u00a0years): post hoc analyses from the COMET study. Ann Rheum Dis 71:989\u2013992","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2240_CR18","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1136\/annrheumdis-2012-201519","volume":"71","author":"P Studenic","year":"2012","unstructured":"Studenic P, Smolen JS, Aletaha D (2012) Near misses of ACR\/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis 71(10):1702\u20131705","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-013-2240-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2240-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:57:25Z","timestamp":1559120245000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-013-2240-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,11]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["2240"],"URL":"https:\/\/doi.org\/10.1007\/s10067-013-2240-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,11]]}}}